Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. (LNTH) from its SEC filings: 2025 revenue $1.5 billion (+0% vs the year before), net margin 15%, free cash flow $390.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $1.5 billion |
| Revenue growth | +0% |
| Net income | $233.6 million |
| Net margin | 15.2% |
| Free cash flow | $390.1 million |
| Diluted EPS | $3.41 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +3% |
| Cash | $593.3 million |
| Long-term debt | $557.7 million |
| Share count, 1 year | -4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.